Company research
Summit Therapeutics Inc.
CIK 1599298Updated Sep 29, 2026
SecuritySMMT · NASDAQ · equity
Name history
Summit Therapeutics plc · through Sep 17, 2020Summit Corp plc · through Jan 30, 2015
SMMT price & chart
Loading TradingView…
NASDAQ:SMMT on TradingView ↗About the company
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit was founded in 2003 and the company’s shares are listed on the Nasdaq Global Market (symbol “SMMT”). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.
In the news
High-Stakes October has these Biotechs Entering Crucial Stretch ↗
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Aug 12, 2025, 04:30 ET Share this article Share to X Share this article Share to X LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm , ↗
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 1.01, 3.02, 5.03, 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Other Events
Items 8.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 751,182,000Source | 435,560,000Source | 202,949,000Source | 664,168,000Source |
| Property, Plant and Equipment, NetUSD | 1,059,000Source | 254,000Source | 204,000Source | 906,000Source |
| GoodwillUSD | 2,001,000Source | 1,864,000Source | 1,893,000Source | 1,798,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | 0Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 225,266,000Source | 104,862,000Source | 71,425,000Source | 348,607,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 0Source | 349,000Source |
| Assets, CurrentUSD | 720,301,000Source | 423,750,000Source | 189,712,000Source | 656,712,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,537,000Source | 10,519,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 20,616,000Source | 7,144,000Source | 5,859,000Source | 4,175,000Source |
| Other Assets, NoncurrentUSD | 7,205,000Source | 1,850,000Source | 4,322,000Source | 577,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 92,322,000Source | 46,812,000Source | 125,257,000Source | 537,514,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 7,754,000Source | 7,376,000Source | 7,017,000Source | 2,110,000Source |
| Additional Paid in CapitalUSD | 2,947,805,000Source | 1,598,230,000Source | 1,066,381,000Source | 504,767,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,294,159,000Source | -1,214,573,000Source | -993,258,000Source | -378,330,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,540,000Source | -2,285,000Source | -2,448,000Source | -1,893,000Source |
| Stockholders' Equity Attributable to ParentUSD | 658,860,000Source | 388,748,000Source | 77,692,000Source | 126,654,000Source |
| Liabilities and EquityUSD | 751,182,000Source | 435,560,000Source | 202,949,000Source | 664,168,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 72,988,000Source | 41,729,000Source | 20,405,000Source | 38,782,000Source |
| Operating Lease, Liability, CurrentUSD | 3,388,000Source | 3,765,000Source | 2,809,000Source | 1,690,000Source |
| Accounts Payable, CurrentUSD | 20,292,000Source | 4,636,000Source | 2,667,000Source | 355,000Source |
| Operating Lease, Liability, NoncurrentUSD | 17,502,000Source | 3,453,000Source | 3,290,000Source | 2,763,000Source |
| Other Liabilities, NoncurrentUSD | 1,832,000Source | 1,630,000Source | 1,562,000Source | 1,429,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 32,100,000Source | 19,554,000Source | 8,783,000Source | 10,664,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 186,242,000Source | — |
| Short-term InvestmentsUSD | 488,182,000Source | 307,487,000Source | 114,817,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 732,420,000Source | 50,981,000Source | 14,108,000Source | 11,948,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | 0Source | -359,000Source | -975,000Source |
| Increase (Decrease) in Accounts PayableUSD | 15,303,000Source | 2,015,000Source | 2,263,000Source | -4,132,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -322,930,000Source | -142,106,000Source | -76,760,000Source | -41,582,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -174,310,000Source | -205,341,000Source | -587,774,000Source | -624,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 657,000Source | 139,000Source | 128,000Source | 624,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 617,533,000Source | 381,227,000Source | 86,513,000Source | 620,244,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 120,395,000Source | 33,762,000Source | -577,182,000Source | 576,816,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 225,582,000Source | 105,187,000Source | 71,425,000Source | 648,607,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 8,806,000Source | 10,650,000Source | 434,000Source |
| Income Taxes Paid, NetUSD | 0Source | 0Source | 52,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 732,420,000Source | 50,981,000Source | 14,108,000Source | 11,948,000Source |
| Amortization of Intangible AssetsUSD | — | 0Source | 0Source | 914,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 186,242,000Source | — |
| DepreciationUSD | 146,000Source | 89,000Source | 198,000Source | 349,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -610,000Source | -97,000Source | 613,000Source | -4,109,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 320,000Source | -229,000Source | 812,000Source | -2,614,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 0Source | 0Source | 109,000Source | — |
| General and Administrative ExpenseUSD | 556,750,000Source | 60,527,000Source | 30,265,000Source | 26,743,000Source |
| GoodwillUSD | 2,001,000Source | 1,864,000Source | 1,893,000Source | 1,798,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | 0Source | 0Source | 8,468,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | 0Source | 8,686,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | 1,513,000Source |
| Net Income (Loss) Attributable to ParentUSD | -1,079,586,000Source | -221,315,000Source | -614,928,000Source | -78,782,000Source |
| Nonoperating Income (Expense)USD | 14,838,000Source | 13,369,000Source | -5,278,000Source | -6,693,000Source |
| Operating ExpensesUSD | 1,094,424,000Source | 226,311,000Source | 610,651,000Source | 87,210,000Source |
| Other Nonoperating Income (Expense)USD | -53,000Source | 0Source | -252,000Source | 304,000Source |
| Other Operating Income (Expense), NetUSD | — | 313,000Source | 1,001,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | 104,686,000Source | 100,000,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 399,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 0Source | 0Source | 705,000Source |
| Operating Income (Loss)USD | — | -225,998,000Source | -609,650,000Source | -72,089,000Source |
| Other Nonoperating Income (Expense)USD | -53,000Source | 0Source | -252,000Source | 304,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -1,079,586,000Source | -221,315,000Source | -614,928,000Source | -78,782,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -1,079,586,000Source | -221,315,000Source | -614,928,000Source | -78,782,000Source |
| Earnings Per Share, BasicUSD per share | -1.44Source | -0.31Source | -0.99Source | -0.41Source |
| Earnings Per Share, DilutedUSD per share | -1.44Source | -0.31Source | -0.99Source | -0.41Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 747,702,265Source | 718,541,896Source | 619,646,180Source | 193,336,063Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 747,702,265Source | 718,541,896Source | 619,646,180Source | 193,336,063Source |
| Interest Expense (non-operating)USD | 0Source | 8,686,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 0Source | 0Source | 914,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -610,000Source | -97,000Source | 613,000Source | -4,109,000Source |
| General and Administrative ExpenseUSD | 556,750,000Source | 60,527,000Source | 30,265,000Source | 26,743,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -752,857,000Source | -22,275,000Source | -115,118,000Source | -31,914,000Source |
| Interest ExpenseUSD | — | — | — | 4,401,000Source |
| Interest Expense, DebtUSD | — | — | 16,461,000Source | — |
| Investment Income, InterestUSD | — | — | — | 1,513,000Source |
| Nonoperating Income (Expense)USD | 14,838,000Source | 13,369,000Source | -5,278,000Source | -6,693,000Source |
| Operating ExpensesUSD | 1,094,424,000Source | 226,311,000Source | 610,651,000Source | 87,210,000Source |
| Other Operating IncomeUSD | — | — | 1,001,000Source | 14,416,000Source |
| Other Operating Income (Expense), NetUSD | — | 313,000Source | 1,001,000Source | — |
| Research and Development ExpenseUSD | — | — | 59,471,000Source | 51,999,000Source |
Filing attachments
d178892dex991.htm · 8-K · 2026-09-29
Exhibit 99.1 AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price Summit Also Enters into Clinical Trial Collaboration with AstraZeneca to Evaluate Ivonescimab in Combination with Sonesitatug Vedotin in Multiple Gastrointestinal Cancers Summit & AstraZeneca Plan to Enter into a Cli…
Read attachment ↗d274712dex991.htm · 8-K · 2025-10-22
EX-99.1 4 d274712dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Summit Therapeutics Raises $500 Million in Private Placement Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday’s Closing Price of $18.74 Miami, Florida, October 22, 2025 - Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech institutional and individua…
Read attachment ↗